MedPath

Management of Polycystic Ovarian Syndrome in young wome

Not Applicable
Conditions
Polycystic Ovary Syndrome PCOS
Registration Number
PACTR201710002641118
Lead Sponsor
Emaduldin Seyam
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Female
Target Recruitment
200
Inclusion Criteria

A randomized, double-blind controlled study was performed using combined Simvastatin and metformin with PCOS unmarried women in a tertiary care centre in Upper Egypt. The diagnosis of PCOS was based on the availability of the three diagnostic criteria of the Rotterdam consensus, namely clinical and biochemical evidence of hyperandrogenaemia (Ferriman-Gallwey score (FGS), free androgen index (FAI) respectively), oligomenorrhea or amenorrhea and polycystic ovaries on transabdominal ultrasound

Exclusion Criteria

Women recruited had no concurrent illness, and were not on any prescription or over-the-counter medication which might affect insulin sensitivity, lipids or ovarian function including hormonal contraceptives for the preceding six months. 21-hydroxylase deficiency, hyperprolactinaemia, Cushing¿s disease and androgen-secreting tumors were excluded by appropriate tests. All women were young unmarried and not planning to marry at least till the end of study period. Recruited women were advised not to change their lifestyle, including physical activity or dietary habits, during the study period

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Spontaneous ovulation improvement
Secondary Outcome Measures
NameTimeMethod
Improvement of the clinical, and biochemical abnormalities assocaited with PCOS
© Copyright 2025. All Rights Reserved by MedPath